What monitoring is required for patients with sickle cell disease (SCD) receiving hydroxyurea?

Updated: May 12, 2021
  • Author: Joseph E Maakaron, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Patients receiving hydroxyurea require frequent blood testing and monitoring, with special attention to development of leukopenia and/or thrombocytopenia. A good continuous doctor-patient relationship and rapport must exist to ensure that potential toxicity is identified at its onset.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!